Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Welltone is a branded generic pharmaceutical formulation marketed by SBM Enterprises (SBM Pharmaceuticals), an Indian PCD (Propaganda Cum Distribution) company. It is typically formulated as a combination of methylcobalamin (Vitamin B12), alpha lipoic acid, pyridoxine (Vitamin B6), and folic acid, available in dosage forms such as capsules. Welltone functions as a neuroprotective agent and nutritional supplement, primarily indicated for the management of peripheral neuropathy, diabetic neuropathy, and various vitamin deficiencies. Methylcobalamin supports nerve myelination and regeneration, while alpha lipoic acid acts as a potent antioxidant that reduces oxidative stress in nerve tissues and improves microcirculation. Pyridoxine and folic acid serve as essential cofactors in metabolic processes, including the regulation of homocysteine levels, which is critical for cardiovascular and neurological health.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Welltone.